Goodwin Procter advised Grey Wolf Therapeutics on the deal, while DLA Piper advised Pfizer Ventures and Earlybird Venture Capital. Grey Wolf Therapeutics announced its $49 million Series B...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here